Sheila Gujrathi, M.D., Joins Ambrx Board of Directors

Feb 24, 2014, 09:00 ET from Ambrx Inc.

SAN DIEGO, Feb. 24, 2014 /PRNewswire/ -- Ambrx Inc. today announced that Sheila Gujrathi, M.D., has joined its board of directors. Dr. Gujrathi is currently the chief medical officer at Receptos (Nasdaq: RCPT) where she is responsible for the clinical development of therapeutic candidates for the treatment of immune and metabolic diseases.

"Sheila is an industry veteran with significant experience in immunologic and oncologic drug development," said Lawson Macartney, Ph.D., chief executive officer of Ambrx. "Her leadership in directing and evaluating drug development programs will be invaluable as we continue to advance our own and partnered drug candidates of best-in-class biotherapeutics and antibody-drug conjugates."

Prior to joining Receptos in 2011, Dr. Gujrathi was vice president of the global clinical research group in immunology at Bristol‑Myers Squibb (BMS) where she was responsible for the late-stage clinical development of Orencia®, Nulojix® and other compounds being developed for rheumatoid arthritis, solid organ transplant, systemic lupus erythematosus, juvenile idiopathic arthritis and inflammatory bowel disease. Dr. Gujrathi was at Genentech from 2002 to 2008 where she held roles of increasing responsibility in the immunology, tissue growth and repair clinical development group and served as the Avastin franchise team leader. Dr. Gujrathi has also been a management consultant in McKinsey & Company's healthcare practice.

Dr. Gujrathi holds a bachelor of science in biomedical engineering and a doctor of medicine from Northwestern University. She completed her internal medicine internship and residency at Brigham and Women's Hospital, Harvard Medical School, and additional fellowship training in Allergy/Immunology at UCSF and Stanford. About Ambrx Ambrx Inc. is a clinical stage biopharmaceutical company using an expanded genetic code to create best-in-class biotherapeutics, including antibody-drug conjugates (ADCs), bispecific antibodies and proteins with improved pharmacologic properties. The company is developing ARX201, a long-acting growth hormone that has successfully completed Phase 2b clinical trials in growth hormone deficiency. In addition to its most recent ADC collaborations with Merck, Astellas and Bristol-Myers Squibb, Ambrx has collaborations to discover and develop products incorporating Ambrx technology with Bristol-Myers Squibb, Eli Lilly and several undisclosed companies. Ambrx is advancing a robust portfolio of product candidates that are optimized for efficacy, safety and ease of use in multiple therapeutic areas.  For additional information, visit

Media Contact:  David Schull  (212) 845-4271


SOURCE Ambrx Inc.